Our PAH Franchise

Opsumit Logo

Opsumit® (macitentan)

Opsumit® (macitentan) is an orally available endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target of developing an ERA to address efficacy and safety.

Tracleer® bosentan logo

Tracleer® (bosentan)

Actelion’s lead product, Tracleer® (bosentan) – an endothelin receptor antagonist – was the first oral treatment approved for PAH.

Veletri® epoprostenol for injection logo

Veletri® (Epoprostenol for Injection)

Veletri® (Epoprostenol for Injection) is intravenous prostacyclin. Unlike other epoprostenol formulations approved for PAH, Veletri is stable at room temperature (77 F, 25 C) for up to 48 hours when administered immediately upon reconstitution and dilution, making the use of frozen gel packs unnecessary.

Ventavis® iloprost logo

Ventavis® (iloprost)

Ventavis® (inhaled iloprost) is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclin (PGI2) – a naturally occurring molecule that causes blood vessels to dilate, limits cellular hypertrophy, and inhibits platelet aggregation.

Our Specialty products

Valchlor (mechlorethamine) logo

Valchlor® (mechlorethamine)

Valchlor® (mechlorethamine) gel 0.016% is applied topically once-a-day and dries on the skin. Valchlor is the only US Food and Drug Administration (FDA) approved topical formulation of mechlorethamine, a chemotherapeutic agent for the treatment of early stage mycosis fungoides, a type of Cutaneous T-Cell Lymphoma.

Zavesca (miglustat) picture


Miglustat, the active ingredient of Zavesca®, is an orally available molecule with a large volume of distribution, which was developed for the treatment of type 1 Gaucher disease (GD1).